Please assess the completion status of the following clinical trial:

Trial Title: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40 to 85~* Male~* Prostate adenocarcinoma on biopsy~* Clinical stage T1c/T2a/T2b, N0, M0/Mx with no lesion larger than 2cc in volume~* The following biopsy findings (biopsy must have MRI visualization and be within 6 months of planned NanoTherm® treatment):~  * A positive biopsy for prostate cancer from the MRI-visualized lesion, at least one of which must be Gleason 3+4 (grade group 2)~* Lesion must be visualized by Multiparametric Magnetic Resonance Imaging (MP-MRI) on a scan that is less than 6 months old~* Patient expresses a preference for active surveillance, rather than surgery or radiation, to manage prostate cancer~* Based on the evaluation of the study investigator, appropriate for instillation of NanoTherm® under anesthesia based on location and size of the clinical target volume (CTV)~Exclusion Criteria:~* Previous treatment for cancer with radiation, androgen deprivation (including LHRH-agonists or antagonists or antiandrogens), or surgery for prostate cancer~* Active urinary tract infection~* Metallic implants below the neck~* Gleason 3+4 or higher cancer on prostate biopsy outside of the planned CTV~* Gleason 4+3 or higher on any prostate biopsy~* Hematological abnormality indicating increased risk of bleeding or clotting, for example low platelet count or anemia~* Participation concurrently in another clinical trial for prostate disease or in the last 30 days~* Known hypersensitivity to Axumin®

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ablation Arm (Type: EXPERIMENTAL): Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).